Market Synopsis of Vesicoureteral Reflux Market:
Vesicoureteral Reflux (VUR), is a condition in which urine flows backward, from the bladder into the ureters/kidneys. The normal flow of urine is unidirectional from the kidneys to the bladder via the ureters. The backflow is prevented by a 1-way, flap valve at the vesicoureteral junction called ureterovesicular valve. There are two types of VUR, primary VUR and secondary VUR. Primary VUR is caused due to insufficient length of the ureter as compared to its diameter, which causes reduced capacity of the valvular mechanism to control the urine flow. Primary VUR is caused by congential abnormality. Secondary VUR is caused due to overwhelming of ureters' valvular mechanism due to increased bladder pressures associated with obstruction, which may be anatomical or functional. The pressure may distort the ureterovesicular valve needing surgical measures to correct the deformity. These signs and symptoms can include a strong and persistent urge to urinate which is often associated with a burning sensation when urinating, high frequency of urinating in small amounts, occurrence of blood in the urine often with a strong smell, fever, abdominal pain etc. VUR also cause urinary tract infection (UTI) due to backflow of urine which increases the chances of infection.
The market for Vesicoureteral Reflux Market is driven by factors such as growing prevalence of urinary tract infection, genetic predisposition and occurrence at birth (congenital), increasing screening etc. It must also be noted that white population and girls are at a higher risk of developing VUR. Considering all these factors, the Vesicoureteral Reflux Market is expected to reach US$ 1.1 billion by the end of 2023, this market is projected to growing at a CAGR of ~ 4.7 % during 2017-2023.
The growing awareness and the availability of advanced biocompatible products such as dextranomer and hyaluronic acid gels which are injected to treat VUR are expected to make a positive impact on the market. VUR Injection marks an advancement over the current surgery treatment as it is minimally invasive and requires less hospital stay. Development of surgical robots will drive the future market as they are more precise, cause less trauma. However, the minimally invasive surgeries are more expensive which will act as a drag on the market. Over all the rising per capita income and the growing acceptance of the surgeries across the globe will drive the future market. The critical market restraints are complications and discomfort associated with VUR diagnosis and treatment, invasive nature of the open surgery, infections etc.
Key players of Vesicoureteral Reflux Market:
Key players profiled in Vesicoureteral Reflux Market report are Salix Pharmaceuticals, Q-Med Scandinavia Inc., Cook Medical, Salix Pharmaceuticals, Ltd., Bayer AG, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., and others.
The Vesicoureteral Reflux Market is segmented on the basis of types, diagnosis, drug treatment, surgery and end users.
Based on types, the Vesicoureteral Reflux Market has been segmented as primary VUR and secondary VUR. Based on the diagnosis, the market has been segmented as cystography, voiding cystourethrogram (VCUG), ultrasound, scintigraphy, urinalysis and others. Based on the drug treatment, the market has been segmented as quinolones, aminoglycosides, β-lactam, azoles and others. Based on the surgery, the market has been segmented as open surgery, robotic-assisted laparoscopic surgery, endoscopic surgery and others. Based on the end users, the market has been segmented as hospitals and clinics, academics and research and others.
Sources: Mayo Clinic, MRFR Analysis.
US accounts for the maximum market share due to favorable insurance penetration, excellent reimbursement scenario and greater expenditure on healthcare. The faster market uptake of new technology and devices in the US is also an important driver of the Vesicoureteral Reflux Market. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is expected to have the most future potential and it is estimated to be led by China and India. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The regions of Africa are expected to witness a moderate growth due to poor economic and political conditions and poor healthcare penetration.
Vesicoureteral Reflux Market, by Region
The report for Vesicoureteral Reflux Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
Frequently Asked Questions (FAQ) :
Caucasian girls and women combined with hereditary traits and prevalence of urinary tract infection (UTI) are major growth drivers of the global vesicoureteral reflux market.
Vesicoureteral reflux market is expected to be valued at USD 1.1 billion by 2023.
Vesicoureteral reflux market is expected to perform exceptionally at a CAGR of 4.7% from 2017 to 2023.
The U.S. has the largest share in the global vesicoureteral reflux market.
Salix Pharmaceuticals, Ltd., Bayer AG, Pfizer Inc., Q-Med Scandinavia Inc., Salix Pharmaceuticals, F. Hoffmann-La Roche Ltd., Cook Medical, Novartis AG, and others are major players of the global vesicoureteral reflux market.